IL7 and neoplasm: Tumor growth inhibition was more pronounced with intratumoral Ad.IL-7/B7.1 treatment compared to Ad.βgal, leading to 70% (7/10) tumor-free long-term survivors in the Ad.IL-7/B7.1 group, but there were no survivors in the Ad.βgal group (Table 1).